I lead AstraZeneca’s late-stage oncology 文件夹 of innovative medicines and immunotherapies through global clinical development and regulatory submissions.
In my role, I oversee a 团队 of 更多 than 850 talented clinical and clinical operations colleagues around the world, who are currently responsible for a broad 文件夹 of 12 cancer drugs and 更多 than 120 studies, most of which are Phase 3, spanning multiple indications.
Our work at AstraZeneca is among the most exciting in my 20 years in cancer research. We have a rich and growing oncology pipeline including both new molecular entities and currently marketed therapies that have the potential to address unmet needs in many hard-to-treat cancers. Every day, we are pushing the boundaries of science and challenging the status quo to deliver practice-changing medicines to redefine the treatment of cancer.
Over the last several years, I have lectured extensively on topics including immunotherapy clinical trials, breast cancer and clinical development of PI3K inhibitors. I have published on a wide range of cancer topics, authoring nearly 50 peer-reviewed papers and 更多 than 100 conference abstracts. I have also generated several patents for cancer treatment combinations and regimens.
A medical doctor by training, I began my career in medical oncology after serving as a physician in the Italian Army. I earned my medical degree from Marche Polytechnic University and received medical oncology training at the Royal Marsden Hospital, Kaplan Comprehensive Cancer Center and the European Institute of Oncology.
We have the potential to disrupt cancer treatment paradigms in multiple tumours. For patients, this means new medicines that could transform their lives and potentially one day find a cure. This work is what has driven my career as a medical oncologist.
2008-2014: Several Novartis awards including President’s Award, Vision Award and Region Europe Award永利皇冠
1999: Italian League Against Cancer’s Leonida Gennarelli Grant 永利皇冠
1998: A. Girombelli Prize for Best Oncology Dissertation永利皇冠
2017 - 2019
2010 - 2017
2008 - 2010
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).永利皇冠
Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhrling K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J. Ann Oncol. 2018 Nov 1;29(11):2163-2174. Publication link.
Phase II study of buparlisib (BKM120) in combination with trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.永利皇冠
Pistilli B, Pluard T, Urruticoechea A, Farci D, Kong A, Bachelot T, Chan S, Han HS, Jerusalem G, Urban P, Robinson D, Mouhaër SL, Tomaso ED, Massacesi C, Saura C. Breast Cancer Res Treat. 2018 Apr;168(2):357-364. Publication link.
First-Line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.永利皇冠
Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr. Lancet. 2017 Mar 4;389(10072):917-929. Publication link.
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.永利皇冠
Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Lancet Oncol. 2017 Jul;18(7):904-916. Publication link.
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.永利皇冠
Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Lancet Oncol. 2017 Jul;18(7):874-886. Publication link.
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.永利皇冠
Overcoming Phosphatidylinositol 3-Kinase (PI3K) activation in breast cancer: Emerging PI3K inhibitors.永利皇冠
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.永利皇冠
Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, Beck JT, Di Tomaso E, Sternberg DW, Massacesi C, Hirawat S, Dirix L, Baselga J. Clin Cancer Res. 2014 Apr 1;20(7):1935-45. Publication link.
Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab.永利皇冠
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.永利皇冠
Guichard SM, Curwen J, Bihani T, D'Cruz CM, Yates JW, Grondine M, Howard Z, Davies BR, Bigley G, Klinowska T, Pike KG, Pass M, Chresta CM, Polanska UM, McEwen R, Delpuech O, Green S, Cosulich SC. Mol Cancer Ther. 2015 Nov;14(11):2508-18. Publication link.